Overton was set to face a key vote today in the Senate health committee. While members had outstanding questions and concerns, panel chairman Sen. Bill Cassidy (R-La.) seemed to think those had been addressed and Overton was going to clear the committee and head to the floor.
But that didn’t happen.
Cassidy said he was taken by surprise because he thought Overton had the votes to advance. Sen. Patty Murray (D-Wash.) said on Tuesday that she was committed to ensuring Overton's confirmation did not advance, citing her past criticisms of the abortion pill mifepristone.
"We have decades of proof that medication abortion is safe and effective. Millions upon millions of women have used this medication," Murray said in a statement. "But in our hearing, Dr. Overton would not say what the science has said for years now: that the abortion pill is safe and effective. At the same time, she also tried to avoid acknowledging her past claims that the abortion pill was ‘dangerous’—perhaps because she knows they are embarrassingly wrong."
FDA thrives on stability and predictability, and the lack of a confirmed leader makes that difficult.
Under former commissioner Marty Makary, the agency had lost trust and was viewed as politically charged. There has been a period of relative calm under acting commissioner Kyle Diamantas, but he has reportedly declined to take the role permanently.
The next head of the agency will have to navigate many of the same headwinds — political interference, funding cuts and balancing the demands of the “Make America Healthy Again” (MAHA) movement with the MAGA White House — that Makary faced.
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pushing untested peptides with virtually no restrictions. Anti-abortion leaders and lawmakers want the agency to restrict access to the abortion pill mifepristone.
With just two months left until Democrats are set to take control of Congress, the Trump administration will likely have to contend with sending a new FDA nominee before a Senate controlled 56-44 by Democrats.